盘龙药业: 2025-034 关于董事会换届选举公告

Core Viewpoint - The announcement details the upcoming election of the fifth board of directors for Shanxi Panlong Pharmaceutical Group Co., Ltd., which will consist of 9 members, including 5 non-independent directors, 3 independent directors, and 1 employee representative director [1][3]. Board Election Details - The fifth board of directors will be composed of 9 members: 5 non-independent directors, 3 independent directors, and 1 employee representative director [1]. - The board's election will be conducted through a cumulative voting system for both non-independent and independent directors [3]. Candidate Nomination - The board's nomination committee has approved the following candidates for the fifth board: - Non-independent directors: Xie Xiaolin, Wu Jie, Xie Xiaofeng, Zhang Dezhuz, Huang Jilin - Independent directors: Niu Xiaofeng, Wang Mancang, Wang Peng [2]. Candidate Qualifications - All nominated candidates have been confirmed to meet the qualifications required for directors of a listed company, in accordance with relevant laws and regulations [2]. - The number of directors who are also senior management or employee representatives will not exceed half of the total board members, and independent directors will account for at least one-third of the board [2]. Term and Transition - The term for the new board of directors will be three years, starting from the date of approval at the company's second extraordinary general meeting in 2025 [3]. - Current board members will continue to fulfill their duties until the new board is officially in place [3]. Independent Director Tenure - Independent directors cannot serve more than six consecutive years, and two current independent directors are approaching the end of their terms [3].